Needham Maintains Buy on AtriCure, Raises Price Target to $64
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Needham analyst Mike Matson maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $45 to $64.
Needham analyst Mike Matson maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $45 to $64.